Results 81 to 90 of about 6,882 (175)

An Ischemic stroke related to eltrombopag use in a patient with idiopathic thrombocytopenic purpura [PDF]

, 2016
Idiopatik trombositopenik purpura (ITP) tedavisinde kullanılmakta olan eltrombopag gibi trombopoetin reseptör (TpoR) agonistlerinin iskemik serebrovasküler hastalık oluşturma riski nadir görülmektedir.
Arslan, Demet, Kelkitli, Engin
core   +1 more source

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia

Haematologica, 2018
Few therapeutic options are available for patients with aplastic anemia who are ineligible for transplantation or refractory to immunosuppressive therapy. Eltrombopag was recently shown to produce trilineage responses in refractory patients. However, the
Etienne Lengline, Bernard Drenou, Pierre Peterlin, Olivier Tournilhac, Julie Abraham, Ana Berceanu, Brigitte Dupriez, Gaelle Guillerm, Emmanuel Raffoux, Flore Sicre de Fontbrune, Lionel Ades, Marie Balsat, Driss Chaoui, Paul Coppo, Selim Corm, Thierry Leblanc, Natacha Maillard, Louis Terriou, Gerard Socié, Regis Peffault de Latour   +19 more
doaj   +1 more source

Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?

Folia Medica Indonesiana, 2016
Idiopathic thrombocytopenic purpura is a autoimmune disease characterized thrombocytopenia casued by excessive platelet destruction. However, both platelet destruction and reduced thrombopoietin level are occurred in some cases. Therefore, new management
Jefri Pratama Susanto
doaj   +1 more source

Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag

, 2015
Severe refractory ITP is clinically challenging and a variety of single or combination chemotherapies have been tried with limited outcome. We report a case of ITP that was unresponsive to multiple agents including high-dose steroid, IVIG, Rho(D) immune ...
Anju Nair, Anwer, Faiz, Yun, Seongseok, Ravitharan Krishnadashan, H. Joachim Deeg, Yusuf Ahmad, Faiz Anwer, Seongseok Yun, Ahmad, Yusuf, Deeg, H. Joachim, Nair, Anju, Krishnadashan, Ravitharan   +11 more
core   +1 more source

Long‐term efficacy and safety of romiplostim plus immunosuppressive therapy as first‐line treatment in patients with aplastic anaemia: 2‐year interim analysis of observational study of two clinical trials [PDF]

Br J Haematol
British Journal of Haematology, Volume 209, Issue 4, Page 1955-1959, October 2026.
Lee J, Hosokawa K, Jang J, Obara N, Sawa M, Usuki K, Oshikawa G, Kizaki M, Nagafuji K, Lin T, Hanamoto H, Mun Y, Kawakita T, Imada K, Cheong J, Park S, Tabayashi T, Gamou M, Murotani K, Yamazaki H.   +19 more
europepmc   +2 more sources

Eltrombopag-Induced Cerebral Venous Thrombosis: A Case Report and Literature Review

Case Reports in Hematology
Immune thrombocytopenia purpura (ITP) is initially treated with steroids, but TPO-RAs such as eltrombopag are used for chronic cases. Though effective, eltrombopag has been linked to thromboembolic events, with cerebral venous thrombosis (CVT) being a ...
I-Wei Lin, Ken-Hong Lim, Yen-Chang Huang, Meng-Ta Sung   +3 more
doaj   +1 more source

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome

, 2020
Thrombocytopenia is a severe complication for patients with myelodysplastic syndrome (MDS). Eltrombopag increases platelet count in MDS patients but its combination with azacitidine elicited controversial results.
Ilaria Zangrilli (8690994), Marianna Criscuolo (5847453), Francesco D’Alò (5509262), Luana Fianchi (3143730), Giulia Falconi (8691000), Livio Pagano (293851), Valerio De Stefano (3143709), Elisa Cupelli (8690997), Emiliano Fabiani (8691003), Stefan Hohaus (4556929)   +9 more
core   +1 more source

Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)Research in context

EClinicalMedicine
Summary: Background: Recombinant human thrombopoietin (rhTPO) at a fixed dose of 300 U/kg/day for 2 weeks has demonstrated good efficacy and safety in adults with immune thrombocytopenia (ITP).
Yunfei Chen, Ting Sun, Da Gao, Wei Wang, Zeping Zhou, Guangxun Gao, Yi Wang, Hu Zhou, Yanping Song, Yinghui Lai, Zhenyu Yan, Jinsong Yan, Jie Bai, Lei Zhang   +13 more
doaj   +1 more source

Experiencia del uso fuera de indicación de Eltrombopag en el tratamiento de la trombocitopenia asociada a tumores sólidos [PDF]

, 2015
Objetivo: Describir los resultados del uso fuera de indicación de eltrombopag en pacientes con trombocitopenia limitante de tratamiento quimioterápico y tumores sólidos.
García Coronel,María, Martínez Ortiz,María José, Cerezuela Fuentes,Pablo, Martínez Penella,Mónica, García Lagunar,María Henar, Gutiérrez-Meca Maestre,Dolores Paula   +5 more
core   +1 more source

Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial

Eltrombopag combined with horse antithymocyte globulin and cyclosporine A (CSA) is the standard of care for patients with severe aplastic anemia who are not eligible for stem cell transplantation.
Flore Sicre de Fontbrune, Felicitas R Thol, Beatrice Drexler, Antonia Beitzen-Heineke, Alexander Röth, Michael Heuser, Philippe Schafhausen, Sixten Körper, Regina Theresia Herbst, Mathias Hänel, Hubert Schrezenmeier, Fabian Beier, Britta Höchsmann, Jörg Westermann, Michaela Schwarz, Regis Peffault de Latour, Tim H. Brümmendorf, Astrid Marx-Hofmann, Jens P. Panse   +18 more
core   +1 more source